• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".

作者信息

Rand Kim, Ramos-Goñi Juan Manuel, Akmaz Bülent, Solé-Feu Laia, Armario-Hita José-Carlos

机构信息

Maths in Health B.V., Schoolstraat 21, 6343CD, Klimmen, The Netherlands.

Global Market Access, Pricing and Medical Affairs, Barcelona, Spain.

出版信息

Dermatol Ther (Heidelb). 2024 Mar;14(3):823-827. doi: 10.1007/s13555-024-01107-1. Epub 2024 Mar 5.

DOI:10.1007/s13555-024-01107-1
PMID:38438784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10965869/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/945d/10965869/cd388e839312/13555_2024_1107_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/945d/10965869/cd388e839312/13555_2024_1107_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/945d/10965869/cd388e839312/13555_2024_1107_Fig1_HTML.jpg

相似文献

1
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".对《致编辑的信：关于“中度至重度特应性皮炎中乐布利单抗与度普利尤单抗长期疗效维持及不良事件发生率的匹配调整间接比较”》的回复
Dermatol Ther (Heidelb). 2024 Mar;14(3):823-827. doi: 10.1007/s13555-024-01107-1. Epub 2024 Mar 5.
2
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'.致编辑的信：关于“中度至重度特应性皮炎中乐必妥单抗与度普利尤单抗长期疗效维持及不良事件发生率的匹配调整间接比较”
Dermatol Ther (Heidelb). 2024 Mar;14(3):819-821. doi: 10.1007/s13555-024-01106-2. Epub 2024 Feb 16.
3
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis.中度至重度特应性皮炎中，乐必妥珠单抗与度普利尤单抗长期疗效维持及不良事件发生率的匹配调整间接比较
Dermatol Ther (Heidelb). 2024 Jan;14(1):169-182. doi: 10.1007/s13555-023-01058-z. Epub 2023 Oct 28.
4
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis.对《中度至重度特应性皮炎中乐布利珠单抗与度普利尤单抗长期疗效维持及不良事件发生率的匹配调整间接比较》的更正
Dermatol Ther (Heidelb). 2024 Jan;14(1):183-185. doi: 10.1007/s13555-023-01076-x.
5
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.来布立izumab治疗中度至重度特应性皮炎青少年患者的安全性和有效性：一项为期52周的开放标签3期研究。
Dermatol Ther (Heidelb). 2023 Jul;13(7):1517-1534. doi: 10.1007/s13555-023-00942-y. Epub 2023 Jun 15.
6
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
7
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).度普利尤单抗治疗青少年中重度特应性皮炎的长期疗效和安全性：III 期开放标签扩展试验（LIBERTY AD PED-OLE）的第 52 周结果。
Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14.
8
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.在长达 4 年的时间里，接受度普利尤单抗治疗的中重度特应性皮炎成人患者的总体感染风险没有增加。
Adv Ther. 2023 Jan;40(1):367-380. doi: 10.1007/s12325-022-02322-y. Epub 2022 Nov 1.
9
Dupilumab in the treatment of moderate-to-severe atopic dermatitis.度普利尤单抗治疗中重度特应性皮炎
Expert Rev Clin Immunol. 2017 Apr;13(4):301-310. doi: 10.1080/1744666X.2017.1292134. Epub 2017 Feb 15.
10
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.

本文引用的文献

1
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.Lebrikizumab 在中重度特应性皮炎中的疗效和安全性：两项随机双盲安慰剂对照 III 期临床试验的 52 周结果。
Br J Dermatol. 2023 May 24;188(6):740-748. doi: 10.1093/bjd/ljad022.
2
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.多种度普利尤单抗剂量方案在特应性皮炎初始成功治疗后的疗效和安全性：一项随机临床试验。
JAMA Dermatol. 2020 Feb 1;156(2):131-143. doi: 10.1001/jamadermatol.2019.3617.